Electronic Caregiver Expands Access to Intelligent Care Across New ...

(PR-inside.com) LAS CRUCES, NM / ACCESS Newswire / July 6, 2026 /Electronic Caregiver, Inc., New Mexico's pioneering healthcare technology company, today announced a series of milestones that significantly expand access to intelligent care throughout the state while reinforcing New Mexico's emergence as a national center for healthcare innovation. The company has achieved New Mexico Medicaid in-network provider status, received approval under the state's Developmental Disabilities (DD) Waiver Program , and recently launched its next-generationAdvanced Primary Care Management platform featuring new integrations with state and federal Health Information Exchanges to support more connected, informed, and longitudinal care. Together, these advancements enable Electronic Caregiver to ..

Electronic Caregiver Expands Access to Intelligent Care Across New Mexico While Advancing the Rio Grande Health Technology and Services Corridor

Biohacking Pioneer and Coffee Mogul Dave Asprey Honored with 2026 Mindshare ...

(PR-inside.com) Celebrating two decades of leadership in biohacking, human optimization, and health innovation CORONADO, CA / ACCESS Newswire / July 6, 2026 / Dave Asprey, four-time New York Times bestselling author and widely recognized as the Father of Biohacking, has been named a recipient of the 2026 Pinnacle Award. Presented annually, the Pinnacle Award recognizes a leader whose work creates a lasting and positive impact on global health and wellness. Asprey is the CEO of Upgrade Labs and host of the Webby Award-winning podcast, The Human Upgrade, with over 1,000 episodes. Over more than two decades, Dave Asprey has fundamentally changed the way ..

Biohacking Pioneer and Coffee Mogul Dave Asprey Honored with 2026 Mindshare Summit Pinnacle Award

Celebrating two decades of leadership in biohacking, human optimization, and health innovation

Active Motif Announces Exclusive Global Distribution Agreement with Arima Genomics for Advanced 3D Genomics Solutions

Agreement expands Active Motif's research genomics portfolio while supporting Arima's strategic focus on its clinical diagnostics platform CARLSBAD, Calif., July 6, 2026 /PRNewswire/ -- Active Motif, a leading provider of epigenetics and multiomic solutions to mechanistic, translational,...

AMO Pharma Announces Update on Scientific Advice for Registrational Clinical Study of AMO-02 in Congenital Myotonic Dystrophy Type 1 Following Meetings with the U.S. Food and Drug Administration, the U.K. Medicines and Healthcare products Regulatory Agency and Health Canada

Based on regulatory agency feedback, the Company plans a registrational study that will evaluate hospitalization as the primary outcome measure, supported by multiple functional assessments as secondary outcome measures. LONDON, July 6, 2026 /PRNewswire/ -- AMO Pharma Limited ("AMO...

HelloNation Explains Personal Injury Evidence and Comparative Negligence Featuring Family Law Attorney Mark E. Zimmer

The article outlines how evidence, medical records, and Pennsylvania fault laws affect personal injury claims after an accident. READING, Penn., July 6, 2026 /PRNewswire/ -- What steps should someone take after an accident to help protect their legal rights? Mark E. Zimmer, Family Law...

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass., July 06, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced that, effective July 1, 2026, the company granted non-qualified stock options to purchase 107,060 shares of its common stock to three new employees under Xilio Therapeutics’ 2022 Inducement Stock Incentive Plan.

Alcon and RxSight Announce Collaboration to Develop Adjustable PCIOLs

ALISO VIEJO, Calif., July 06, 2026 (GLOBE NEWSWIRE) -- Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, and RxSight, Inc. (NASDAQ: RXST), an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced a non-exclusive collaboration to jointly develop adjustable presbyopia-correcting intraocular lenses (PCIOLs).

Context Therapeutics Added to Russell 2000® and Russell 3000® Indexes

PHILADELPHIA, July 06, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, today announced that the Company was added to the small-cap Russell 2000 ® and the broad-market Russell 3000 ® Indexes, effective at the close of U.S. equity markets on June 26, 2026.

MedStar Health Offers New Thumb Joint Replacement for Thumb Arthritis

D.C. and Baltimore firsts bring "mini hip replacement" innovation to thumb arthritis care. COLUMBIA, Md., July 6, 2026 /PRNewswire/ -- MedStar Health hand surgeons in both D.C. and Baltimore became the first in their respective regions to perform a break-through treatment for patients...

Update DEA Hearing July 6: Harvard Expert Testifies State Dispensary ...

(PR-inside.com) DOJ Says the Controlled Substances Act Protects Legitimate Scientific Research. MMJ Says the Government Should Start Treating It That Way. "The government cannot tell companies to spend years following the FDA's scientific pathway, then dismiss those same efforts as a 'pocketbook interest' when they seek equal treatment under the law. We didn't build a market-we built a medicine." stated Duane Boise, President & CEO, MMJ International Holdings WASHINGTON, DC / ACCESS Newswire / July 6, 2026 /MMJ International Holdings, Inc. (MMJIH), together with MMJ BioPharma Cultivation, Inc. and MMJ BioPharma Labs, Inc., today responded to the Department of Justice's recent filing before ..